Pinned Tweet
Welcome to the Substance Over Noise community!
A free room to discuss each issue, share papers, and argue the evidence on GLP-1s, longevity, lipids, and obesity medicine.
Join here: read.michaelalbertmd.com/com…
1
7
878
$20 weight loss consultation is just a dispensing fee.
You can't provide an adequate medical consultation for $20. You are basically just dispensing a med for that cost.
At the “JAMA and National Academies Present the Future of Obesity Care Delivery: Systems, Care Models, and Research” session at #OW2026, Dr. Louis Aronne emphasized that coverage—not demand—is the bottleneck.
“Care has to start with coverage.” —Dr. Aronne
Everyone on X lately: “Introducing our new peptide line!”
Suggested taglines:
“Because your body deserves drugs before evidence.”
“Because demand is all the justification we need.”
“Because being predatory is in our nature.”
🤦🏼♂️
Given what we know so far about NAION, particularly the role of underlying optic nerve anatomy, I’d be cautious about describing a GLP-1 medication as the sole cause. That doesn’t rule out the drug contributing to an event in someone already susceptible. Whether that contribution is enough to establish legal liability is beyond my pay grade.
How will this affect my practice? I will likely recommend updated eye exam in people with type 2 diabetes seeking GLP1 therapy.
It’s rare to have this much fun at work. @DrNadolsky and @SummerDietitian deserve a lot of credit for the culture we’re building at Vineyard, and I’m grateful to be part of this team.
Today, I want to give a special shout-out to my boss and brother-in-crime, Spencer.
He’s right there in the trenches with us and understands what it means to serve. He does so many small things for patients that most people never see. I won’t put him on blast with the details…for now.
This past weekend, he flew the Vineyard team to ObesityWeek and paid for everything. The guy gives as much of a damn about his staff as he does about his patients.
He’s a rare one, and he’ll probably hate me for this post. 😜
GDF-15 is real nausea biology. The claim that it explains GLP-1 nausea is a hypothesis only, AND‼️ the published data point the other way.
GLP-1 nausea already has a mapped circuit. In mice, GLP1R neurons in the area postrema drive aversion while GLP1R neurons in the NTS drive satiety (Huang, Nature 2024). No mitochondrial distress signal required. 🫡
The GDF-15 idea has also been tested. Mice lacking GDF15 or its receptor GFRAL still cut food intake on liraglutide like normal mice (Frikke-Schmidt, Mol Metab 2019). In humans, titrating liraglutide to 3.0 mg over 5 weeks did not move total or intact GDF-15 in a randomized crossover trial (Valenzuela-Vallejo, Metabolism 2022). It was flat again at 26 weeks against placebo (Hoekx, Exp Physiol 2024).
So where is the spike? Uncontrolled clinic labs can't tell us, because caloric restriction and metformin each raise GDF-15 on their own‼️😬
Slow titration for nausea is good medicine. It doesn't need an invented mitochondrial injury story to justify it, and "your mitochondria are under excessive strain" is a heavy thing to tell patients with zero published data behind it.
For a decade, we asked one question of every obesity drug: how much weight?
ObesityWeek 2026 retired it.
The new question is which patient, which drug, which dose, and for how long.
Here are the 5 talks that change practice this week 🧵
7/ What to do Monday morning:
1. Prepare an answer for parents asking about GLP-1s under age 12
2. Quote −18.5% for teen tirzepatide
3. Flag patients with severe OSA or disabling knee OA
4. Stop equating max dose with max benefit
5. Revisit phentermine when GLP-1 access fails
Subscribe and follow @michaelalbertmd for more or follow my long-form writing: read.michaelalbertmd.com/
4
510
I'm bullish on amylin serving as a novel MOA to prevent and potentially treat bone demineralization and related disorders.
1/ ObesityWeek 2026 had 1,050 abstracts, and the headlines went to the biggest weight-loss percentages.
The ones that will change clinic next year answer a different question: how do patients keep the weight off, and keep it good quality?
My top 10, with caveats 🧵
8/ What to do Monday morning:
1. Stop treating max dose as the only maintenance plan.
2. Raise oral maintenance with patients who are tired of injecting.
3. Ask patients over 60 about strength and function, not just weight.
4. Check every "up to" number against the full paper.
2
3
389
Subscribe and follow @michaelalbertmd and my long-form writing: read.michaelalbertmd.com/
3
381








